» Articles » PMID: 21190052

Dietary Inhibitors of Monoamine Oxidase A

Overview
Specialties Neurology
Physiology
Date 2010 Dec 31
PMID 21190052
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Inhibition of monoamine oxidase is one way to treat depression and anxiety. The information now available on the pharmacokinetics of flavonoids and of the components of tobacco prompted an exploration of whether a healthy diet (with or without smoking) provides active compounds in amounts sufficient to partially inhibit monoamine oxidase. A literature search was used to identify dietary monoamine oxidase inhibitors, the levels of these compounds in foods, the pharmacokinetics of the absorption and distribution, and tissue levels observed. An estimated daily intake and the expected tissue concentrations were compared with the measured efficacies of the compounds as inhibitors of monoamine oxidases. Norharman, harman and quercetin dietary presence, pharmacokinetics, and tissue levels were consistent with significant levels reaching neuronal monoamine oxidase from the diet or smoking; 1,2,3,4-tetrahydroisoquinoline, eugenol, 1-piperoylpiperidine, and coumarin were not. Quercetin was equipotent with norharman as a monoamine oxidase A inhibitor and its metabolite, isorhamnetin, also inhibits. Total quercetin was the highest of the compounds in the sample diet. Although bioavailability was variable depending on the source, a healthy diet contains amounts of quercetin that might give sufficient amounts in brain to induce, by monoamine oxidase A inhibition, a small decrease in neurotransmitter breakdown.

Citing Articles

Methanolic Extract of Leaves Prevents LPS-Induced Depressive Like Behavior in Experimental Mice.

Arshad H, Ahmad F, Lodhi A Drug Des Devel Ther. 2022; 16:4179-4204.

PMID: 36514526 PMC: 9741839. DOI: 10.2147/DDDT.S383054.


Effect of a Vegan Diet on Alzheimer's Disease.

Katonova A, Sheardova K, Amlerova J, Angelucci F, Hort J Int J Mol Sci. 2022; 23(23).

PMID: 36499257 PMC: 9738978. DOI: 10.3390/ijms232314924.


Pharmacological effects and therapeutic potential of natural compounds in neuropsychiatric disorders: An update.

Asgharian P, Quispe C, Herrera-Bravo J, Sabernavaei M, Hosseini K, Forouhandeh H Front Pharmacol. 2022; 13:926607.

PMID: 36188551 PMC: 9521271. DOI: 10.3389/fphar.2022.926607.


Lifestyle Adjustments in Long-COVID Management: Potential Benefits of Plant-Based Diets.

Storz M Curr Nutr Rep. 2021; 10(4):352-363.

PMID: 34506003 PMC: 8429479. DOI: 10.1007/s13668-021-00369-x.


Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.

Tarpley M, Oladapo H, Strepay D, Caligan T, Chdid L, Shehata H Eur J Pharm Sci. 2021; 162:105821.

PMID: 33781856 PMC: 8404221. DOI: 10.1016/j.ejps.2021.105821.


References
1.
Egert S, Wolffram S, Bosy-Westphal A, Boesch-Saadatmandi C, Wagner A, Frank J . Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr. 2008; 138(9):1615-21. DOI: 10.1093/jn/138.9.1615. View

2.
Hollman P, Katan M . Absorption, metabolism and health effects of dietary flavonoids in man. Biomed Pharmacother. 1997; 51(8):305-10. DOI: 10.1016/s0753-3322(97)88045-6. View

3.
Haleagrahara N, Radhakrishnan A, Lee N, Kumar P . Flavonoid quercetin protects against swimming stress-induced changes in oxidative biomarkers in the hypothalamus of rats. Eur J Pharmacol. 2009; 621(1-3):46-52. DOI: 10.1016/j.ejphar.2009.08.030. View

4.
de Boer V, Dihal A, van der Woude H, Arts I, Wolffram S, Alink G . Tissue distribution of quercetin in rats and pigs. J Nutr. 2005; 135(7):1718-25. DOI: 10.1093/jn/135.7.1718. View

5.
Moon Y, Wang L, DiCenzo R, Morris M . Quercetin pharmacokinetics in humans. Biopharm Drug Dispos. 2008; 29(4):205-17. DOI: 10.1002/bdd.605. View